Table 2.

Occurrence of solicited adverse events within 7 days, and serious adverse events, important medical events, and unsolicited adverse events within 30 days of first or second vaccinations in children

		Monovalent OPV2		Novel OPV2-c1 (high dose)		Novel OPV2-c2 (high dose)
		Dose 1 (n=50)	Dose 2 (n=47)	Dose 1 (n=47)	Dose 2 (n=45)	Dose 1 (n=53)	Dose 2 (n=52)
Serious adverse events		0	1 (2%)	0	1 (2%)	1 (2%)	0
	Vaccine-related serious adverse events	0	0	0	0	0	0
Important medical events		0	0	1 (2%)	0	0	0
	Vaccine-related important medical events	0	0	0	0	0	0
Solicited adverse events
	Any	10 (20%)	9 (19%)	17 (36%)	12 (27%)	14 (26%)	12 (23%)
	Grade 1	9 (18%)	7 (15%)	13 (28%)	10 (22%)	8 (15%)	10 (19%)
	Grade 2	0	2 (4%)	3 (6%)	1 (2%)	3 (6%)	1 (2%)
	Grade 3	1 (2%)	0	1 (2%)	1 (2%)	3 (6%)	1 (2%)
	Causally associated (adverse reactions)	1 (2%)	0	5 (11%)	10 (22%)	4 (8%)	4 (8%)
Unsolicited adverse events
	Any	37 (74%)	24 (51%)	35 (74%)	32 (71%)	41 (77%)	42 (81%)
	Causally associated	0	0	1 (2%)	0	0	0

No serious adverse events or important medical events were considered to be serious adverse reactions or important medical reactions (ie, causally associated with vaccination). OPV2=type 2 oral poliovirus vaccine.